Nebula Research & Development LLC Makes New Investment in GeneDx Holdings Corp. (NASDAQ:WGS)

Nebula Research & Development LLC purchased a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 4,918 shares of the company's stock, valued at approximately $378,000.

Other hedge funds have also modified their holdings of the company. MCF Advisors LLC increased its position in GeneDx by 107.7% during the fourth quarter. MCF Advisors LLC now owns 351 shares of the company's stock valued at $27,000 after acquiring an additional 182 shares during the last quarter. Sterling Capital Management LLC grew its holdings in shares of GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company's stock worth $27,000 after purchasing an additional 316 shares during the last quarter. Global Retirement Partners LLC purchased a new position in GeneDx in the 4th quarter worth about $28,000. KLP Kapitalforvaltning AS bought a new stake in GeneDx during the 4th quarter valued at about $200,000. Finally, Evolution Wealth Advisors LLC purchased a new stake in GeneDx in the 4th quarter valued at about $202,000. 61.72% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wells Fargo & Company dropped their price target on GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a research report on Thursday. The Goldman Sachs Group increased their target price on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Wednesday, February 19th. TD Cowen boosted their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a "buy" rating in a report on Tuesday, January 7th. Finally, TD Securities dropped their price objective on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating on the stock in a research note on Thursday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $78.14.

Insider Activity

In other news, CEO Katherine Stueland sold 46,594 shares of the company's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $89.62, for a total value of $4,175,754.28. Following the completion of the transaction, the chief executive officer now owns 1,720 shares in the company, valued at approximately $154,146.40. This represents a 96.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Kevin Feeley sold 388 shares of the stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $113.09, for a total transaction of $43,878.92. Following the completion of the transaction, the chief financial officer now directly owns 3,337 shares in the company, valued at $377,381.33. This trade represents a 10.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 139,390 shares of company stock valued at $13,043,288. 27.30% of the stock is currently owned by corporate insiders.

GeneDx Price Performance

WGS stock traded up $4.91 during trading on Friday, hitting $67.23. The stock had a trading volume of 2,456,763 shares, compared to its average volume of 717,917. The company's 50-day moving average price is $94.30 and its two-hundred day moving average price is $82.72. GeneDx Holdings Corp. has a twelve month low of $18.80 and a twelve month high of $117.75. The stock has a market capitalization of $1.89 billion, a P/E ratio of -34.30 and a beta of 1.93. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.17. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The firm had revenue of $87.12 million for the quarter, compared to the consensus estimate of $79.90 million. As a group, research analysts predict that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.